Studies from Carnegie Mellon University in the Area of Nanoparticles Reported (Branched-tail Lipid Nanoparticles for Intravenous Mrna Delivery To Lung Immune, Endothelial, and Alveolar Cells In Mice).

Researchers from Carnegie Mellon University have developed branched-tail lipid nanoparticles (LNPs) for the delivery of mRNA drugs to lung immune, endothelial, and alveolar cells in mice. LNPs have been widely used as safe and effective delivery systems, but their efficacy has been limited to liver and immune cell targets. The researchers synthesized and tested over 580 ionizable lipidoids, with more than 40 enabling protein expression in mice. The most potent LNPs contained branched tails and selectively targeted natural killer and dendritic cells in the lungs without the use of toxicity-prone cationic lipids. This novel vehicle has the potential to unlock RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders. [Extracted from the article]